In August 2025, the Nasdaq-100 index showed modest overall performance, with a gain of 0.9%, but three companies significantly outperformed the rest, each with gains of 20% or more. Leading the charge was semiconductor giant Intel, which posted a considerable 23% increase amid a notable financing arrangement with the U.S. government.
The deal involved the Trump administration acquiring 9.9% of Intel’s stock, creating a unique financial relationship that provided the company with a much-needed boost after a challenging July. Despite this upswing, Intel’s stock price remains approximately 10% below its 2025 highs, raising questions among shareholders about whether the agreement will benefit or dilute stock value in the long term.
Following closely was AppLovin, the mobile marketing expert, which achieved a remarkable 22.5% gain during the same period. The company announced its second-quarter results on August 6, outperforming Wall Street estimates. Following the release, AppLovin’s stock surged by 12% in a single day, driven by a staggering 77% year-over-year revenue increase and a 164% rise in unadjusted net profits. The company’s stock has been steadily climbing, reaching new all-time highs with almost daily gains.
Idexx Laboratories also made waves in August, experiencing a 21.1% rise. The pet healthcare company impressed investors with its quarterly results, showcasing strong growth in consumables and recurring service revenues. A newly launched cancer test for dogs performed well in North America, bolstering sales and contributing to a successful international expansion strategy.
While these three companies stood out against a backdrop of largely stagnant market trends, investors are cautioned to conduct thorough research before making investment decisions. As notable successes in their respective fields, Intel, AppLovin, and Idexx Laboratories present unique opportunities, albeit with varying risk profiles and market positions.
